Dr Reddy’s Laboratories shares rallied more than 9 percent intraday after settlement agreement with US-based Vivus to resolve a long-pending patent litigation related to anti-obesity pill (or weight management capsules) Qsymia.
The settlement agreement permits the company to begin selling a generic version of Qsymia on June 1, 2025, or earlier under certain circumstances. In the event of a launch earlier than June 1, 2025, Vivus will receive a royalty on sales of the generic version of Qsymia.
Qysmia is a combination of phentermine and topiramate extended-release sold in capsule form. The drug is used to manage chronic overweight in adults with obesity symptoms.
You may also like:
|Sensex, Nifty rangebound; RBI’s MPC meet outcome awaited||Sensex, Nifty continue to be sluggish ahead of RBI policy; Europe mixed|